Status:
COMPLETED
Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injections in Japanese healthy adults and elderly subjects.
Eligibility Criteria
Inclusion
- Japanese
- Healthy adults aged ≥20 and ≤50 years (Step 1) or healthy elderly aged ≥65 and ≤80 years (at the time of informed consent)
- Body mass index (BMI) is ≥18.0 and \<30.0 kg/m\^2 (at screening)
Exclusion
- Participants with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- Having alcohol or drug dependence, etc.
Key Trial Info
Start Date :
June 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04914520
Start Date
June 11 2021
End Date
December 16 2021
Last Update
December 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Corporation Association Shinanokai Shinanozaka Clinic
Shinjuku-Ku, Tokyo, Japan, 160-0017